Capmatinib 200mg Tablets — MET Inhibitor for Non-Small Cell Lung Cancer With MET Exon 14 Skipping Mutation
Rahika® (Capmatinib) — Targeted MET Inhibitor for Non-Small Cell Lung Cancer
A Sourcing Guide for Hospitals and Oncology Centres
Rahika® (Capmatinib) is a selective inhibitor of the MET receptor tyrosine kinase indicated, according to the manufacturer’s approved prescribing information, for the treatment of adults with metastatic non-small cell lung cancer (NSCLC) whose tumours have a mutation that leads to MET exon 14 skipping. As with all oncology therapies, the decision to prescribe Rahika, including biomarker testing and patient selection, rests entirely with the treating oncologist, in accordance with the approved label. This page provides sourcing and procurement information for hospitals and pharmacies, not clinical or treatment guidance.
As both a trusted medicine distributor in Delhi and a licensed pharmaceutical distributor in Delhi, A.K. Pharma supplies genuine Rahika (Capmatinib) 200mg to hospitals, oncology centres, and pharmacies across India, manufactured by Novartis India Ltd. Hospitals managing broader lung cancer caseloads often source Rahika alongside other targeted therapies and supportive medicines available through A.K. Pharma’s full product range.
Rahika contains Capmatinib, a small-molecule tyrosine kinase inhibitor that selectively targets the MET receptor, a signalling protein implicated in a distinct molecular subtype of non-small cell lung cancer.
MET Exon 14 Skipping Mutations in NSCLC:
According to published oncology literature, a small but clinically significant subset of NSCLC cases, more frequently observed in older patients, harbour mutations that cause exon 14 of the MET gene to be “skipped” during RNA splicing. This alteration removes a regulatory region normally responsible for degrading the MET receptor after activation, leading to prolonged and excessive MET signalling. This sustained signalling drives tumour cell proliferation and survival, functioning as an oncogenic driver in this specific molecular subgroup, which is generally identified through companion diagnostic testing on tumour tissue or blood-based genomic testing. This mechanism is distinct from other targeted lung cancer pathways such as ALK rearrangements, addressed by therapies like Spexib (Ceritinib), or PD-1/PD-L1 checkpoint signalling, addressed by immunotherapies such as Tishtha (Nivolumab).
Capmatinib’s Mechanism: By selectively inhibiting the MET kinase domain, Capmatinib blocks the excessive, sustained signalling caused by MET exon 14 skipping mutations, according to the manufacturer’s prescribing information, addressing the specific molecular driver in this NSCLC subgroup.
Full prescribing information is available at the FDA label for Capmatinib, with additional background on MET signalling available via the National Cancer Institute’s NSCLC resource.
GEOMETRY mono-1 Trial (Capmatinib in MET Exon 14 Skipping NSCLC)
Published in the New England Journal of Medicine (2020), the pivotal GEOMETRY mono-1 trial evaluated Capmatinib in patients with metastatic NSCLC harbouring MET exon 14 skipping mutations, across both treatment-naive and previously treated patient cohorts. Key findings included substantial overall response rates in both cohorts, with notably higher response rates observed in treatment-naive patients compared to those previously treated, along with meaningful duration of response. This trial supported regulatory approval and demonstrated Capmatinib’s activity as both a first-line and later-line treatment option in this molecular subgroup.
Additional data from GEOMETRY mono-1 also demonstrated intracranial response in patients with brain metastases, an important consideration given the propensity of NSCLC to metastasise to the central nervous system. For broader context on biomarker-driven lung cancer treatment approaches, the American Society of Clinical Oncology (ASCO) publishes ongoing clinical guidance for oncologists.
Rahika is available as:
| Presentation | Strength |
|---|---|
| Rahika 200mg Tablets | 200mg per tablet |
Rahika is also available in other strengths per the manufacturer’s full product range, with dosing regimen determined by the prescribing oncologist in accordance with the approved label.
Metastatic Non-Small Cell Lung Cancer With MET Exon 14 Skipping Mutation:
MET exon 14 skipping biomarker testing is required before initiating Rahika therapy, using a validated companion diagnostic test, per the approved prescribing information.
For detailed indication information refer to MedlinePlus Capmatinib.
Strong First-Line Response Rates
GEOMETRY mono-1 demonstrated notably higher response rates in treatment-naive patients compared to previously treated patients, supporting Rahika’s use as an effective first-line option in MET exon 14 skipping-positive NSCLC.
Demonstrated Intracranial Activity
Response data in patients with brain metastases is a clinically relevant consideration given the frequency of central nervous system involvement in metastatic NSCLC.
Biomarker-Directed Precision Approach
By requiring MET exon 14 skipping testing before treatment, Rahika represents a precision oncology approach, directing therapy specifically toward tumours confirmed to carry the relevant molecular alteration.
Option Across Treatment Lines
Demonstrated activity in both treatment-naive and previously treated patients provides flexibility in treatment sequencing decisions made by the treating oncologist.
Dosing of Rahika is determined by the prescribing oncologist according to the approved label. General administration information from the manufacturer’s prescribing information includes:
Monitoring (per manufacturer prescribing information):
Full dosing guidelines are available in the manufacturer’s official prescribing information and should always be followed exactly as directed by the treating oncologist.
Rahika is prescribed by oncologists for:
Rahika is prescribed by oncologists specialising in lung cancer management. A.K. Pharma supplies Rahika to hospitals and oncology centres across Delhi and India.
Common side effects reported in clinical trials include peripheral oedema, nausea, fatigue, vomiting, dyspnoea, and decreased appetite.
Serious side effects include:
Interstitial Lung Disease/Pneumonitis: Severe pulmonary adverse events have been reported; prompt evaluation of new or worsening respiratory symptoms is recommended per the approved label, with treatment interruption or discontinuation guidance provided in the prescribing information.
Hepatotoxicity: Elevated liver enzymes have been reported; liver function monitoring is recommended per the approved prescribing information.
Renal Impairment: Effects on renal function have been reported; monitoring is recommended per the approved label.
Peripheral Oedema: Reported as a common adverse event; monitoring and management guidance is provided in the approved prescribing information.
Full side effect information is available at FDA Capmatinib Safety Information.
As a responsible medicine distributor in Delhi, A.K. Pharma stores all oncology medicines including Rahika under manufacturer-recommended conditions ensuring product integrity for every supply.
Rahika (Capmatinib) is manufactured by Novartis India Ltd. Capmatinib received regulatory approval for metastatic NSCLC with MET exon 14 skipping mutations, both as first-line therapy and for previously treated patients. A.K. Pharma supplies only genuine Rahika sourced from authorised distributors. Learn more about Novartis’s oncology portfolio directly from the manufacturer.
Q. What is Rahika used for?
Rahika (Capmatinib) is used to treat adults with metastatic non-small cell lung cancer whose tumours harbour a MET exon 14 skipping mutation, either as first-line therapy or following prior systemic treatment.
Q. What is the generic name of Rahika?
The generic name of Rahika is Capmatinib, a MET inhibitor manufactured by Novartis India.
Q. Why is MET exon 14 skipping testing required before starting Rahika?
Rahika is approved specifically for tumours with a MET exon 14 skipping mutation, which drives a distinct molecular subtype of NSCLC. Testing confirms whether a patient’s tumour carries this alteration before treatment is considered.
Q. Is Rahika effective in patients with brain metastases?
Clinical trial data from GEOMETRY mono-1 demonstrated intracranial response in patients with brain metastases, though individual treatment decisions for patients with CNS involvement should be made by the treating oncologist based on the complete clinical picture.
Q. Is Rahika available in India?
Rahika can be supplied to hospitals and oncology centres across India through licensed pharmaceutical distributors. Contact A.K. Pharma — medicine distributor in Delhi and pharmaceutical distributor in Delhi — for availability and pricing.
Q. What is the price of Rahika in India?
Rahika price in India varies by pack size. Contact A.K. Pharma at 011 4172 6999 or WhatsApp +91 9810034827 for current pricing and bulk supply rates.
Q. How to order Rahika from A.K. Pharma?
You can request a quote directly from this page, call us at 011 4172 6999, or WhatsApp us at +91 9810034827 with your requirements and we will respond promptly.
Q. Does A.K. Pharma supply Rahika in bulk?
Yes. A.K. Pharma supplies Rahika in bulk to hospitals and oncology centres across Delhi and India.
📍 E-2/257A, 2nd Floor, Shastri Nagar, New Delhi 110052
📞 011 4172 6999
📱 WhatsApp: +91 9810034827
🌐 akpharma.in
Disclaimer: This page is intended for informational and sourcing/procurement purposes only and does not constitute medical or clinical advice. All treatment decisions, including drug selection and dosing, should be made by a qualified healthcare professional in accordance with the approved prescribing information. A.K. Pharma is a licensed medicine distributor and does not provide clinical guidance.
